PT-2385
Tier C — Watch / tradePT-2385
Targets:EPAS1
Indications (approved):von Hippel-Lindau syndrome, Sarcoma, Renal cell carcinoma, 肾肿瘤, Glioblastoma
Regional status
Synthetic routes & intermediates2 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| PT-2385-014 | 433939-27-6 | 3-bromo-5-fluorophenol |
| PT-2385-015 | 1672665-31-4 | 4-fluoro-7-(methylsulfonyl)-2,3-dihydrospiro[indene-1,2'-[1,3]dioxolane] |
| PT-2385-016 | 1672665-51-8 | 4-(3-bromo-5-fluorophenoxy)-7-(methylsulfonyl)-2,3-dihydrospiro[indene-1,2'-[1,3]dioxolane] |
| PT-2385-017 | 1672665-53-0 | 3-fluoro-5-((7-(methylsulfonyl)-2,3-dihydrospiro[indene-1,2'-[1,3]dioxolan]-4-yl)oxy)benzonitrile |
| PT-2385-018 | 109-73-9 | butan-1-amine |
| PT-2385-019 | 2007115-81-1 | (E)-3-((1-(butylimino)-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile |
| Code | CAS No. | Intermediate |
|---|---|---|
| PT-2385-001 | 1073-72-9 | 4-(methylthio)phenol |
| PT-2385-002 | 67868-84-2 | 2-hydroxy-5-(methylthio)benzaldehyde |
| PT-2385-003 | 2033-24-1 | 2,2-dimethyl-1,3-dioxane-4,6-dione |
| PT-2385-004 | 2004756-76-5 | 6-(methylthio)-2-oxo-2H-chromene-3-carboxylic acid |
| PT-2385-005 | 1672665-65-4 | 3-(2-hydroxy-5-(methylthio)phenyl)propanoic acid |
| PT-2385-006 | 64248-63-1 | 3,5-difluorobenzonitrile |
| PT-2385-007 | 1672665-67-6 | 3-(2-(3-cyano-5-fluorophenoxy)-5-(methylthio)phenyl)propanoic acid |
| PT-2385-008 | - | 3-(2-(3-cyano-5-fluorophenoxy)-5-(methylthio)phenyl)propanoyl chloride |
| PT-2385-009 | 1672665-69-8 | 3-fluoro-5-((7-(methylthio)-1-oxo-2,3-dihydro-1H-inden-4-yl)oxy)benzonitrile |
| PT-2385-010 | 1672665-55-2Available | 3-fluoro-5-((7-(methylsulfonyl)-1-oxo-2,3-dihydro-1H-inden-4-yl)oxy)benzonitrile |
| PT-2385-011 | 5332-73-0 | 3-methoxypropan-1-amine |
| PT-2385-012 | 2004756-77-6 | (E)-3-fluoro-5-((1-((3-methoxypropyl)imino)-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)benzonitrile |
| PT-2385-013 | 1672665-59-6 | 3-((2,2-difluoro-7-(methylsulfonyl)-1-oxo-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile |
Frequently asked questions
What are the approved indications of PT-2385?
Approved indications include: von Hippel-Lindau syndrome, Sarcoma, Renal cell carcinoma, 肾肿瘤, Glioblastoma.
When does the PT-2385 patent expire?
No public expiry year is available for PT-2385 yet; this page updates once verified.
How many synthesis routes are recorded for PT-2385?
2 synthesis routes are recorded; the shortest is 6 steps with 2.15 g total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy PT-2385 intermediates?
1 intermediate CAS of PT-2385 are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for PT-2385 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-09